26,927 findings
- Energy balanceStrong
The policy change of covering anti-obesity medications is likely to increase Medicare costs by low to middle tens of billions of dollars over ten years.
Practitioners should prepare for the potential long-term financial impact of Medicare's coverage of anti-obesity medications.
Supports 2024 - NeuralStrong
Nose-to-brain (N2B) pathways can address limitations of the subcutaneous route for GLP-1 RAs.
Practitioners should explore N2B pathways as a viable alternative for delivering GLP-1 RAs.
Supports 2024 - Energy balanceStrong
Obesity prevalence is projected to grow by 40% in the next decade.
Health professionals should prepare for increased obesity-related health issues.
Supports 2017 - Energy balanceStrong
There were no significant changes in peak VO2 or other cardiovascular measures with HU6 treatment.
HU6 may not improve cardiovascular function despite weight loss.
Refutes 2025New - Energy balanceStrong
25,215 adverse event reports related to tirzepatide were identified, predominantly in the 65 to 85 age group.
Healthcare providers should be aware of the high volume of AE reports in older adults using tirzepatide.
Supports 2024 - Energy balanceStrong
Novel adverse event signals include thyroid mass, medullary thyroid carcinoma, and conditions affecting the reproductive system and breast.
Clinicians should be vigilant for these specific adverse events in patients treated with tirzepatide.
Supports 2024 - CellularStrong
A biomimetic and comparative approach can provide insights into human ageing processes.
Practitioners should consider integrating insights from diverse species to enhance understanding of ageing.
Supports 2021 - MolecularStrong
Multiple hallmarks of ageing have been identified that are fundamental across taxa.
Understanding these hallmarks can guide research and interventions in age-related diseases.
Supports 2021 - CellularStrong
There is a need for renewed focus in the pathophysiology of ageing and age-related disease.
Researchers should explore new avenues in the study of ageing and related diseases.
Supports 2021 - CellularStrong
Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the global population.
Healthcare providers should be aware of the high prevalence of NAFLD in their patient populations.
Supports 2020 - Energy balanceStrong
The direct to consumer genetic testing market is estimated to total about $100 million in 2017.
Practitioners should be aware of the significant financial scale of the DTC genetic testing market.
Supports 2018 - Metabolic adaptationStrong
The need for more effective treatments for obesity is obvious due to the far-reaching effects of the condition.
Healthcare providers should prioritize finding effective obesity treatments.
Supports 2024 - Energy balanceStrong
2/3 of American adults and 1/6 of American children and adolescents are considered either overweight or obese.
Health professionals should be aware of the high prevalence of overweight and obesity in the population.
Supports 2005 - Energy balanceStrong
Innovative engineering technologies are needed to address problems in energy balance, intake, and expenditure associated with obesity.
There is a need for collaboration between engineers and health scientists to develop effective obesity interventions.
Supports 2005 - MolecularStrong
Ingestion of deuterated water results in 2 H enrichment of the body water pool, which is incorporated into tissue proteins.
This highlights a novel approach to studying protein synthesis in muscle tissue.
Supports 2024 - Energy balanceStrong
There is limited clinical trial data on the safety and efficacy of anti-obesity medications for patients with heart failure.
Practitioners should be aware of the limited evidence when considering anti-obesity medications for heart failure patients.
Qualifies 2024 - Energy balanceStrong
The prevalence of obesity has increased markedly in recent decades, constituting major medical and socioeconomic problems worldwide.
Awareness of the obesity epidemic is crucial for public health initiatives.
Supports 2025New - CellularStrong
The most common adverse events associated with semaglutide are gastrointestinal in nature.
Healthcare providers should inform patients about potential gastrointestinal side effects when prescribing semaglutide.
Supports 2024 - HormonalStrong
Ex-DARPin fusion proteins injected at 25 nmol/kg every three days significantly lowered blood glucose, inhibited food consumption, and reduced body weight for 30 days in STZ-induced diabetic mice.
Ex-DARPin fusion proteins may be a promising treatment for managing blood glucose and weight in diabetic patients.
Supports 2023 - MolecularStrong
Ex-DARPin fusion proteins have a comparable half-life of 29-32 hours, which is much longer than that of native Ex (0.5 hours in rats).
Longer half-life of Ex-DARPin fusion proteins may reduce the frequency of administration needed for effective treatment.
Supports 2023 - CellularStrong
Ex-DARPin fusion proteins significantly improved the survival of pancreatic islets in diabetic mice.
Improving pancreatic islet survival could enhance insulin production and overall diabetes management.
Supports 2023 - Energy balanceStrong
There are currently no clear guidelines for the prehabilitation of obese patients with dysglycemia undergoing bariatric surgery.
Healthcare providers should recognize the need for developing guidelines for prehabilitation in this patient population.
Refutes 2022 - Energy balanceStrong
Current community-based lifestyle modification programs are unlikely to be effective in preventing diabetes.
Reassess the design and implementation of lifestyle modification programs for diabetes prevention.
Refutes 2012 - CellularStrong
Patients with coronary artery disease (CAD) have a lower capillary-to-fiber ratio (C/Fi) and capillary-to-fiber perimeter exchange (CFPE) index in Type II fibers compared to healthy controls.
Understanding these differences can inform targeted rehabilitation strategies for CAD patients.
Supports 2020